GLP1减重宝典·2025-08-01 08:32Core Viewpoint - The article discusses President Trump's public letter to 17 major pharmaceutical companies, demanding that they align U.S. prescription drug prices with international markets, particularly those of other developed countries [3][4]. Group 1: Government Actions - Trump signed an executive order in May requiring drug companies to align their prices with international minimums or face government intervention, including the possibility of importing cheaper drugs [4]. - The letter specifies that all drug companies must provide "most favored nation pricing" to Medicaid patients, meaning the lowest price available in OECD countries [6]. - Companies are also required to return excess profits gained from higher prices abroad to U.S. patients and taxpayers [6]. Group 2: Industry Response - Following the announcement, stock prices of several pharmaceutical companies, including Pfizer and Eli Lilly, fell by approximately 2%, with the NYSE Arca Pharmaceutical Index dropping by 3% [6]. - Some companies, like Pfizer and Novartis, expressed willingness to cooperate with the government to improve drug affordability [7]. - Industry experts have raised doubts about the feasibility of implementing these price reductions, suggesting that while some companies may attempt direct sales to patients, comprehensive execution remains challenging [6][7]. Group 3: Market Context - U.S. patients currently pay significantly higher prescription drug costs compared to other developed nations, with some drug prices being three times higher than in other countries [7]. - Pharmaceutical companies argue that high U.S. prices are necessary to fund extensive research and development for new drugs, warning that enforced price reductions could hinder innovation [7].